ResearchDriveLogo.jpg
Rising Cases of Pneumonia during the COVID-19 Anticipated to Boost the Global Pneumonia Therapeutics Market - Exclusive Report [230] by Research Dive
October 13, 2020 05:47 ET | Research Dive
New York, USA, Oct. 13, 2020 (GLOBE NEWSWIRE) -- The latest research report on the global pneumonia therapeutics market by Research Dive reflects the influence of COVID-19 pandemic on the present...
gmi logo.jpg
Pneumonia Therapeutics Market to value USD 2.8 Bn by 2026: Global Market Insights, Inc.
June 23, 2020 04:00 ET | Global Market Insights, Inc
Selbyville, Delaware, June 23, 2020 (GLOBE NEWSWIRE) -- Global Market Insights, Inc. has recently added a new report on pneumonia therapeutics market which estimates the global market valuation...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors
April 20, 2020 08:05 ET | Cocrystal Pharma, Inc.
- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals - ...
FBI LOGO TM.png
Antiviral Drugs Market Worth USD 44.2 billion by 2026, at 3.2% CAGR; Rising Prevalence of HIV to Fuel Growth: Fortune Business Insights™
February 20, 2020 07:37 ET | Fortune Business Insights
Pune, Feb. 20, 2020 (GLOBE NEWSWIRE) -- The global Antiviral Drugs Market is set to gain impetus from the improvements in research collaborations of industry giants to develop state-of-the-art...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses
October 01, 2019 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
CocrystalPharmaInc.jpg
Cocrystal Pharma Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 10, 2019 08:35 ET | Cocrystal Pharma, Inc.
                                                             – Company is well positioned to achieve multiple corporate, clinical and research value-driving milestones in 2019 – BOTHELL, WA, May 10,...
CocrystalPharmaInc.jpg
Cocrystal Pharma Reports 2018 Financial Results and Provides Corporate Overview and Business Outlook
April 01, 2019 08:35 ET | Cocrystal Pharma, Inc.
– Exclusive worldwide license and collaboration agreement with Merck further validates Company’s approach to creating first- and best-in-class antiviral drugs and expected to enable rapid advancement...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
January 03, 2019 08:30 ET | Cocrystal Pharma, Inc.
BOTHELL, WA, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...